Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Quarterly results

Atara Biotherapeutics, Inc. (ATRA) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Quarterly results
Docs: "Atara Biotherapeutics Announces Second Quarter 2023 Financial Results and Operational Progress Discussions With FDA Progressing on Potential BLA Submission for Tab-cel®With Meeting Scheduled To Resolve Remaining Topic of Comparability ATA188 Phase 2 EMBOLD Study Primary Analysis and Communication Will Now Occur in Early November To Include the Last Patient Visits From More Than 90 Patients IND Cleared for Atara's First Allogeneic CAR T, ATA3219, in Relapsed/Refractory B-Cell NHL THOUSAND OAKS, Calif.—August 8, 2023—Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the second quarter 2023, ..."
06/09/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/12/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/08/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/08/2023 8-K Quarterly results
Docs: "Atara Biotherapeutics Announces First Quarter 2023 Financial Results and Operational Progress First Patients Treated in Europe with EBVALLOTM Following Transfer of EC Marketing Authorization to Pierre Fabre; Discussions with FDA Progressing ATA188 Phase 2 EMBOLD Study Primary Data Readout On-Track for October 2023 ATA3219 IND Filing Anticipated End of Q2 2023 THOUSAND OAKS, Calif.—May 8, 2023— Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the first quarter 2023, recent business highlights and key upcoming catalysts. “We are entering an important period of potential value-generat..."
03/31/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/24/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
02/14/2023 SC 13G/A Point72 Asset Management, L.P. reports a 0.2% stake in Atara Biotherapeutics, Inc.
02/14/2023 SC 13G/A MAVERICK CAPITAL LTD reports a 6.6% stake in Atara Biotherapeutics, Inc.
02/14/2023 EFFECT Form EFFECT - Notice of Effectiveness:
02/09/2023 SC 13G/A VANGUARD GROUP INC reports a 7.6% stake in Atara Biotherapeutics Inc.
02/09/2023 SC 13G/A FMR LLC reports a 0.1% stake in ATARA BIOTHERAPEUTICS INC
02/08/2023 10-K Annual Report for the period ended December 31, 2022
02/08/2023 POSASR Form POSASR - Post-effective Amendment to an automatic shelf registration statement:
02/08/2023 8-K Quarterly results
Docs: "Atara Biotherapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Operational Progress Ebvallo™ EU Launch Activities Led by Pierre Fabre to Commence in Q1 2023 Discussions with FDA Progressing on Potential U.S. BLA for Tab-cel® ATA188 Phase 2 EMBOLD Study Primary Data Readout On-Track for October 2023 Cash Runway Extended into Q2 2024 THOUSAND OAKS, Calif.—February 8, 2022—Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year 2022, recent business highlights and key upcoming catalysts for 2023. “Following the landmark approval of Eb..."
02/08/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
02/03/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
01/18/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/06/2023 8-K Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ...
12/20/2022 8-K Quarterly results
12/19/2022 8-K Quarterly results
11/08/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/08/2022 8-K Quarterly results
Docs: "Atara Biotherapeutics Announces Third Quarter 2022 Financial Results and Operational Progress EbvalloTM Positioned to be the First Allogeneic T-Cell Therapy Ever Approved Following CHMP Positive Opinion New ATA188 Biomarker Imaging Data Show Less Brain Atrophy and Possible Remyelination in Patients Achieving Confirmed Disability Improvement in Progressive MS Phase 1study of ATA2271 Enrollment Resumed Conference Call and Webcast Today at 1:30 p.m. PST / 4:30 p.m. EST THOUSAND OAKS, Calif.--November 8, 2022-- Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the third quarter 2022, recent business highligh..."
09/28/2022 8-K Quarterly results
09/27/2022 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "Second Amended and Restated Bylaws of Atara Biotherapeutics, Inc.",
"Second Amended and Restated Bylaws of Atara Biotherapeutics, Inc."
08/08/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/08/2022 8-K Quarterly results
07/22/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
06/24/2022 8-K Quarterly results
05/19/2022 8-K Quarterly results
05/05/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/05/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy